Jefferies reiterates Sarepta stock rating on regulatory pathway By Investing.com

Sarepta will request the FDA convert accelerated approvals for AMONDYS 45 and VYONDYS 53 to traditional approvals and plans to file two supplemental NDAs by end-April, with potential FDA decisions by Feb 2027. Jefferies reiterated a Buy and $30 PT, estimating the regulatory conversion could move the stock 15%–25%; combined Amondys/Vyondys sales were $425M in 2025 and Elevidys could exceed $500M annually. The stock is down ~79% over the past year but analysts via InvestingPro expect profitability this year (~$4.06 EPS); Mizuho raised its PT to $31 while Cantor Fitzgerald stayed Neutral and lowered 2026 revenue estimates. Sarepta also began enrollment in a sirolimus safety protocol for ELEVIDYS and expects Phase I/II siRNA data for DM1 and FSHD in 1H/2H 2026, each opportunity >$1B per Jefferies.

Analysis

The market is pricing a regulatory derisking narrative into the equity but still applies a material program-level discount; conversion of regulatory pathways (and any regulatory acceptance of real-world evidence) functions more like a haircut to the discount rate than a binary revenue event. That compresses required returns for holders and increases the present value of future cash flows, meaning modest positive news can produce outsized multiple expansion even if absolute top-line growth is modest.

Commercial execution and payer dynamics are the more durable drivers of valuation beyond the regulatory binary. Improved label certainty reduces coverage friction, but sustained revenue requires distribution scale, adherence, and durability data to defend price — the latter is the single biggest valve that can open or close payer access over 2–3 years, particularly in high-cost rare-disease settings.

The clinical and safety risk profile of the gene-therapy platform is the asymmetric optionality here: a credible mitigation strategy for liver toxicity materially expands addressable patients and shortens time-to-adoption by centers, while any new safety signal would reintroduce severe downside and tighter monitoring costs. Platform de-risking also raises the value of non-gene pipeline assets by lowering corporate execution risk in valuation models.

Near-term market mechanics matter: implied vol has likely been elevated around regulatory/clinical readouts, making vanilla longs expensive; conversely, limited-float dynamics and concentrated institutional ownership can amplify moves, creating tactical windows to harvest skew. Investors should trade around precise event windows and explicitly size for binary outcomes rather than treating the equity as a smooth growth bet.

Key Decisions for Investors

• Long-dated call-debit spread on SRPT (12–24 month expiry): buy a LEAP call ~12–18 months out and sell a higher strike 24–36 month call to reduce premium. Position size 2–4% of biotech allocation. Rationale: captures regulatory/clinical derisking upside while capping time decay; max loss = net premium, asymmetric upside if multiple expansion occurs.
• Event straddle/strangle around the next confirmatory/regulatory readout (1–3 month window): buy a near-term strangle with defined loss equal to premium, close into volatility crush post-announcement. Use only 1–2% notional. Rationale: monetize elevated idiosyncratic implied vol around outcomes without long-term exposure to commercial execution risk.
• Pair trade: long SRPT equity (1–2% portfolio) funded by short equal-dollar position in a mid-cap biotech ETF/peer (e.g., IBB or a custom basket) for 6–12 months. Rationale: isolates idiosyncratic regulatory upside while hedging sector beta and biotech-wide funding/repricing risk.
• Risk-off hedge: if buying SRPT into event windows, offset with protective put (short-dated) sized to limit drawdown to pre-defined stop (e.g., 20% of position). Rationale: preserves upside optionality while protecting against adverse binary outcomes or safety surprises that can reprice the stock sharply.